{"pmid":32420611,"title":"More on \"Association between ABO blood groups and risk of SARS-CoV-2 Pneumonia\".","text":["More on \"Association between ABO blood groups and risk of SARS-CoV-2 Pneumonia\".","We read with interest the recent report from Li and colleagues describing an association between ABO blood groups and risk of SARS-CoV-2 pneumonia [1]. In an initial study of 265 patients with COVID, the authors observed that blood group O individuals were significantly under-represented amongst patients who required hospitalization for severe COVID-19 infection (p < 0.01). Conversely, blood group A was significantly more common in patients with severe COVID-19 compared to the local population (p=0.017). Subsequently, in a larger validation cohort that included 2153 patients with COVID-19, this ABO effect was reproduced with blood group O again being associated with a significant protective effect (p < 0.001). In keeping with these data, another independent study (n=2173) also reported that blood group O was associated with reduced susceptibility to severe COVID-19.","Br J Haematol","O'Sullivan, Jamie M","Ward, Soracha","Fogarty, Helen","O'Donnell, James S","32420611"],"abstract":["We read with interest the recent report from Li and colleagues describing an association between ABO blood groups and risk of SARS-CoV-2 pneumonia [1]. In an initial study of 265 patients with COVID, the authors observed that blood group O individuals were significantly under-represented amongst patients who required hospitalization for severe COVID-19 infection (p < 0.01). Conversely, blood group A was significantly more common in patients with severe COVID-19 compared to the local population (p=0.017). Subsequently, in a larger validation cohort that included 2153 patients with COVID-19, this ABO effect was reproduced with blood group O again being associated with a significant protective effect (p < 0.001). In keeping with these data, another independent study (n=2173) also reported that blood group O was associated with reduced susceptibility to severe COVID-19."],"journal":"Br J Haematol","authors":["O'Sullivan, Jamie M","Ward, Soracha","Fogarty, Helen","O'Donnell, James S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420611","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16845","weight":0,"_version_":1667254896747872256,"score":9.490897,"similar":[{"pmid":32453863,"title":"COVID-19 & ABO blood group: another viewpoint.","text":["COVID-19 & ABO blood group: another viewpoint.","Juyi Li et al. [1] have recently published \"an association between ABO blood groups and risk of SARS-CoV-2 pneumonia\", an observation already reported a few weeks ago as a MedRxiv preprint by Jiao Zhao et al. [2] and which had a certain impact in the press.","Br J Haematol","Gerard, Christiane","Maggipinto, Gianni","Minon, Jean-Marc","32453863"],"abstract":["Juyi Li et al. [1] have recently published \"an association between ABO blood groups and risk of SARS-CoV-2 pneumonia\", an observation already reported a few weeks ago as a MedRxiv preprint by Jiao Zhao et al. [2] and which had a certain impact in the press."],"journal":"Br J Haematol","authors":["Gerard, Christiane","Maggipinto, Gianni","Minon, Jean-Marc"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32453863","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/bjh.16884","topics":["Mechanism"],"weight":1,"_version_":1667881798466535424,"score":274.8717},{"pmid":32496734,"title":"The effects of blood group types on the risk of COVID-19 infection and its clinical outcome.","text":["The effects of blood group types on the risk of COVID-19 infection and its clinical outcome.","BACKGROUND: COVID-19 (Coronavirus Disease of 2019) is an infectious disease outbreak later on declared as a pandemic, caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). It spreads very rapidly and can result in severe acute respiratory failure. The clinical studies have shown that advanced age and chronic diseases increase the risk of infection. However, influence of the blood groups on COVID-19 infection and its outcome remains to be confirmed. The aim of this study is to investigate whether there exists a relationship between the blood groups of the patients and risk of SARS-CoV-2 infection and the clinical outcomes in COVID-19 patients. MATERIAL AND METHOD: 186 patients with PCR confirmed diagnosis of COVID-19 were included in this study. Age, gender, blood groups, comorbidities, need for intubation and intensive care unit follow up and mortalities of the patients were analyzed retrospectively. 1881 healthy individuals, who presented to the Hacettepe University Blood Bank served as the controls. RESULTS: The most frequently detected blood group was blood group A (57%) amongst the COVID-19 patients. This was followed by the blood group O (24.8%). The blood group types did not affect the clinical outcomes. Blood group A was statistically significantly more frequent among those infected with COVID-19 compared to controls (57% vs 38%, p <0.001; OR: 2.1). On the other hand, the frequency of blood group O was significantly lower in the COVID-19 patients, compared to the control group (24.8% vs 37.2%, p: 0.001; OR: 1.8). CONCLUSIONS: The results of the present study suggest that while the blood group A might have a role in increased susceptibility to the COVID-19 infection, the blood group O might be somewhat protective. However, once infected, blood group type does not seem to influence clinical outcome.","Turk J Med Sci","Goker, Hakan","Aladag Karakulak, Elifcan","Demiroglu, Haluk","Ayaz Ceylan, Caglayan Merve","Buyukasik, Yahya","Inkaya, Ahmet Cagkan","Aksu, Salih","Sayinalp, Nilgun","Haznedaroglu, Ibrahim Celalettin","Uzun, Omrum","Akova, Murat","Ozcebe, Osman Ilhami","Unal, Serhat","32496734"],"abstract":["BACKGROUND: COVID-19 (Coronavirus Disease of 2019) is an infectious disease outbreak later on declared as a pandemic, caused by the SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). It spreads very rapidly and can result in severe acute respiratory failure. The clinical studies have shown that advanced age and chronic diseases increase the risk of infection. However, influence of the blood groups on COVID-19 infection and its outcome remains to be confirmed. The aim of this study is to investigate whether there exists a relationship between the blood groups of the patients and risk of SARS-CoV-2 infection and the clinical outcomes in COVID-19 patients. MATERIAL AND METHOD: 186 patients with PCR confirmed diagnosis of COVID-19 were included in this study. Age, gender, blood groups, comorbidities, need for intubation and intensive care unit follow up and mortalities of the patients were analyzed retrospectively. 1881 healthy individuals, who presented to the Hacettepe University Blood Bank served as the controls. RESULTS: The most frequently detected blood group was blood group A (57%) amongst the COVID-19 patients. This was followed by the blood group O (24.8%). The blood group types did not affect the clinical outcomes. Blood group A was statistically significantly more frequent among those infected with COVID-19 compared to controls (57% vs 38%, p <0.001; OR: 2.1). On the other hand, the frequency of blood group O was significantly lower in the COVID-19 patients, compared to the control group (24.8% vs 37.2%, p: 0.001; OR: 1.8). CONCLUSIONS: The results of the present study suggest that while the blood group A might have a role in increased susceptibility to the COVID-19 infection, the blood group O might be somewhat protective. However, once infected, blood group type does not seem to influence clinical outcome."],"journal":"Turk J Med Sci","authors":["Goker, Hakan","Aladag Karakulak, Elifcan","Demiroglu, Haluk","Ayaz Ceylan, Caglayan Merve","Buyukasik, Yahya","Inkaya, Ahmet Cagkan","Aksu, Salih","Sayinalp, Nilgun","Haznedaroglu, Ibrahim Celalettin","Uzun, Omrum","Akova, Murat","Ozcebe, Osman Ilhami","Unal, Serhat"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32496734","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3906/sag-2005-395","keywords":["blood groups","covid-19","sars-cov-2"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668712823873601536,"score":186.6917},{"pmid":32389803,"title":"Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia.","text":["Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia.","The COVID-19 pandemic and the ensuing barriers to the collection and transport of donor cells, it is often necessary to collect and cryopreserve grafts before initiation of transplant conditioning. The effect on transplant outcomes in non-malignant disease is unknown. This analysis examined the effect of cryopreservation of related and unrelated donor grafts for transplantation for severe aplastic anemia in the US during 2013-2019. Included are 52 recipients of cryopreserved grafts who were matched for age, donor type, and graft type to 194 recipients who received non-cryopreserved grafts. Marginal Cox regression models were built to study the effect of cryopreservation and other risk factors associated with outcomes. We recorded higher 1-year rates of graft failure (HR 2.26, 95% CI 1.17 - 4.35, p=0.01) and of 1-year overall mortality (HR 3.13, 95% CI 1.60 - 6.11, p=0.0008) after transplantation of cryopreserved compared to non-cryopreserved grafts with adjustment for sex, performance score, comorbidity, cytomegalovirus serostatus, and ABO blood group match). Acute and chronic GVHD did not differ between groups. Adjusted probabilities of 1-year survival were 73% (95% 60 - 84) and 91% (95% CI 86 - 94) with cryopreserved and non-cryopreserved grafts, respectively. These data support the use of non-cryopreserved grafts, when possible, for severe aplastic anemia.","Biol Blood Marrow Transplant","Eapen, Mary","Zhang, Mei-Jie","Tang, Xiao-Ying","Lee, Stephanie J","Fei, Ming-Wei","Wang, Hai-Lin","Hebert, Kyle M","Arora, Mukta","Chhabra, Saurabh","Devine, Steven M","Hamadani, Mehdi","D'Souza, Anita","Pasquini, Marcelo C","Phelan, Rachel","Rizzo, J Douglas","Saber, Wael","Shaw, Bronwen E","Weisdorf, Daniel J","Horowitz, Mary M","32389803"],"abstract":["The COVID-19 pandemic and the ensuing barriers to the collection and transport of donor cells, it is often necessary to collect and cryopreserve grafts before initiation of transplant conditioning. The effect on transplant outcomes in non-malignant disease is unknown. This analysis examined the effect of cryopreservation of related and unrelated donor grafts for transplantation for severe aplastic anemia in the US during 2013-2019. Included are 52 recipients of cryopreserved grafts who were matched for age, donor type, and graft type to 194 recipients who received non-cryopreserved grafts. Marginal Cox regression models were built to study the effect of cryopreservation and other risk factors associated with outcomes. We recorded higher 1-year rates of graft failure (HR 2.26, 95% CI 1.17 - 4.35, p=0.01) and of 1-year overall mortality (HR 3.13, 95% CI 1.60 - 6.11, p=0.0008) after transplantation of cryopreserved compared to non-cryopreserved grafts with adjustment for sex, performance score, comorbidity, cytomegalovirus serostatus, and ABO blood group match). Acute and chronic GVHD did not differ between groups. Adjusted probabilities of 1-year survival were 73% (95% 60 - 84) and 91% (95% CI 86 - 94) with cryopreserved and non-cryopreserved grafts, respectively. These data support the use of non-cryopreserved grafts, when possible, for severe aplastic anemia."],"journal":"Biol Blood Marrow Transplant","authors":["Eapen, Mary","Zhang, Mei-Jie","Tang, Xiao-Ying","Lee, Stephanie J","Fei, Ming-Wei","Wang, Hai-Lin","Hebert, Kyle M","Arora, Mukta","Chhabra, Saurabh","Devine, Steven M","Hamadani, Mehdi","D'Souza, Anita","Pasquini, Marcelo C","Phelan, Rachel","Rizzo, J Douglas","Saber, Wael","Shaw, Bronwen E","Weisdorf, Daniel J","Horowitz, Mary M"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389803","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.bbmt.2020.04.027","keywords":["cryopreserved graft","severe aplastic anemia"],"locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666528580263215104,"score":141.10562},{"pmid":32356642,"title":"Can we predict the severity of COVID-19 with a routine blood test?","text":["Can we predict the severity of COVID-19 with a routine blood test?","INTRODUCTION: The ongoing worldwide pandemic of Coronavirus Disease 2019 (COVID-19) has posed a huge threat to global public health. However, whether routine blood test could be used to monitor and predict the severity and prognosis of COVID-19 has never been comprehensively investigated. OBJECTIVES: To provide an overview of the association of markers in routine blood test with the severity of COVID-19. METHODS: PubMed, Embase, Cochrane Library, Wanfang and CNKI database were searched to identify studies reporting the markers in the routine blood test with the severity of COVID-19 until March 20, 2020. STATA software was used for the meta- analysis. RESULTS: A total of 15 studies with 3090 COVID-19 patients were included in this analysis. Patients in non-severe group had fewer white blood cells (WBC) (WMD = -0.85 [109/L], 95% CI = [-1.54, -0.16], P = 0.02) and neutrophils (WMD = -1.57 [109/L], 95% CI = [-2.60, -0.54], P = 0.003), more lymphocytes (WMD = 0.29 [109/L], 95% CI = [0.22, 0.36], P < 0.001) and platelets (WMD = 19.05 [109/L], 95% CI = [3.04, 35.06], P = 0.02), and lower neutrophil-to-lymphocyte ratio (NLR) level (WMD = -2.48, 95% CI = [-3.81, -1.15], P < 0.001), compared with those in severe group. There was no statistical difference in monocytes (WMD = 0.01 [109/L], 95% CI = [-0.01, 0.03], P = 0.029) between these two groups. Sensitivity analysis and meta-analysis based on standard mean difference (SMD) did not change the conclusions about neutrophils, lymphocytes and NLR while the results were inconsistent in WBC and platelets. CONCLUSIONS: Severe patients had more neutrophils, higher NLR level, and fewer lymphocytes than non-severe patients with COVID-19. Measurement of these markers might assist clinicians to monitor and predict the severity and prognosis of COVID-19.","Pol Arch Intern Med","Zeng, Furong","Li, Linfeng","Zeng, Jiling","Deng, Yuhao","Huang, Huining","Chen, Bin","Deng, Guangtong","32356642"],"abstract":["INTRODUCTION: The ongoing worldwide pandemic of Coronavirus Disease 2019 (COVID-19) has posed a huge threat to global public health. However, whether routine blood test could be used to monitor and predict the severity and prognosis of COVID-19 has never been comprehensively investigated. OBJECTIVES: To provide an overview of the association of markers in routine blood test with the severity of COVID-19. METHODS: PubMed, Embase, Cochrane Library, Wanfang and CNKI database were searched to identify studies reporting the markers in the routine blood test with the severity of COVID-19 until March 20, 2020. STATA software was used for the meta- analysis. RESULTS: A total of 15 studies with 3090 COVID-19 patients were included in this analysis. Patients in non-severe group had fewer white blood cells (WBC) (WMD = -0.85 [109/L], 95% CI = [-1.54, -0.16], P = 0.02) and neutrophils (WMD = -1.57 [109/L], 95% CI = [-2.60, -0.54], P = 0.003), more lymphocytes (WMD = 0.29 [109/L], 95% CI = [0.22, 0.36], P < 0.001) and platelets (WMD = 19.05 [109/L], 95% CI = [3.04, 35.06], P = 0.02), and lower neutrophil-to-lymphocyte ratio (NLR) level (WMD = -2.48, 95% CI = [-3.81, -1.15], P < 0.001), compared with those in severe group. There was no statistical difference in monocytes (WMD = 0.01 [109/L], 95% CI = [-0.01, 0.03], P = 0.029) between these two groups. Sensitivity analysis and meta-analysis based on standard mean difference (SMD) did not change the conclusions about neutrophils, lymphocytes and NLR while the results were inconsistent in WBC and platelets. CONCLUSIONS: Severe patients had more neutrophils, higher NLR level, and fewer lymphocytes than non-severe patients with COVID-19. Measurement of these markers might assist clinicians to monitor and predict the severity and prognosis of COVID-19."],"journal":"Pol Arch Intern Med","authors":["Zeng, Furong","Li, Linfeng","Zeng, Jiling","Deng, Yuhao","Huang, Huining","Chen, Bin","Deng, Guangtong"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356642","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.20452/pamw.15331","locations":["Wanfang","monocytes"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495253479425,"score":137.80115},{"pmid":32271456,"title":"Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.","text":["Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.","OBJECTIVE: The Coronavirus disease 2019 (COVID-19) which outbroke in December 2019 is highly contagious with a low cure rate. In view of this, there is an urgent need to find a more appropriate therapeutic scheme against COVID-19. The study aimed to investigate whether lopinavir/ritonavir (LPV/r) in combination with other pneumonia-associated adjuvant drugs has a better therapeutic effect on COVID-19. PATIENTS AND METHODS: Totally 47 patients with COVID-19 infection who were admitted to Rui'an People's Hospital between January 22 and January 29, 2020 were collected. The patients were divided into the test group and the control group according to whether they had been treated with LPV/r or not during hospitalization. Patients in the test group were treated with LPV/r combined with adjuvant medicine, while those in the control group were just treated with adjuvant medicine. The changes of body temperature, blood routine and blood biochemistry between the two groups were observed and compared. RESULTS: Both groups achieved good therapeutic effect with the body temperature of patients decreased gradually from admission to the 10th day of treatment. But the body temperature of patients in the test group decreased faster than that of the control group. Blood routine indexes showed that compared with the control group, the abnormal proportion of white blood cells, lymphocytes and C-reactive protein of the test group could be reduced to some extent. Blood biochemical indexes exhibited that the proportion of patients with abnormal alanine aminotransferase and aspartate aminotransferase in the test group were lower than the control group. The number of days for nCoV-RNA turning negative after treatment was significantly decreased in the test group than that in the control group. CONCLUSIONS: Compared with the treatment of pneumonia-associated adjuvant drugs alone, the combination treatment with LPV/r and adjuvant drugs has a more evident therapeutic effect in lowering the body temperature and restoring normal physiological mechanisms with no evident toxic and side effects. In view of these conclusions, we suggested that the use of LPV/r combined with pneumonia-associated adjuvant drugs in the clinical treatment for patients with COVID-19 should be promoted.","Eur Rev Med Pharmacol Sci","Ye, X-T","Luo, Y-L","Xia, S-C","Sun, Q-F","Ding, J-G","Zhou, Y","Chen, W","Wang, X-F","Zhang, W-W","Du, W-J","Ruan, Z-W","Hong, L","32271456"],"abstract":["OBJECTIVE: The Coronavirus disease 2019 (COVID-19) which outbroke in December 2019 is highly contagious with a low cure rate. In view of this, there is an urgent need to find a more appropriate therapeutic scheme against COVID-19. The study aimed to investigate whether lopinavir/ritonavir (LPV/r) in combination with other pneumonia-associated adjuvant drugs has a better therapeutic effect on COVID-19. PATIENTS AND METHODS: Totally 47 patients with COVID-19 infection who were admitted to Rui'an People's Hospital between January 22 and January 29, 2020 were collected. The patients were divided into the test group and the control group according to whether they had been treated with LPV/r or not during hospitalization. Patients in the test group were treated with LPV/r combined with adjuvant medicine, while those in the control group were just treated with adjuvant medicine. The changes of body temperature, blood routine and blood biochemistry between the two groups were observed and compared. RESULTS: Both groups achieved good therapeutic effect with the body temperature of patients decreased gradually from admission to the 10th day of treatment. But the body temperature of patients in the test group decreased faster than that of the control group. Blood routine indexes showed that compared with the control group, the abnormal proportion of white blood cells, lymphocytes and C-reactive protein of the test group could be reduced to some extent. Blood biochemical indexes exhibited that the proportion of patients with abnormal alanine aminotransferase and aspartate aminotransferase in the test group were lower than the control group. The number of days for nCoV-RNA turning negative after treatment was significantly decreased in the test group than that in the control group. CONCLUSIONS: Compared with the treatment of pneumonia-associated adjuvant drugs alone, the combination treatment with LPV/r and adjuvant drugs has a more evident therapeutic effect in lowering the body temperature and restoring normal physiological mechanisms with no evident toxic and side effects. In view of these conclusions, we suggested that the use of LPV/r combined with pneumonia-associated adjuvant drugs in the clinical treatment for patients with COVID-19 should be promoted."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Ye, X-T","Luo, Y-L","Xia, S-C","Sun, Q-F","Ding, J-G","Zhou, Y","Chen, W","Wang, X-F","Zhang, W-W","Du, W-J","Ruan, Z-W","Hong, L"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271456","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.26355/eurrev_202003_20706","e_drugs":["Aspartic Acid","Lopinavir","lopinavir-ritonavir drug combination","Arginine"],"topics":["Treatment"],"weight":1,"_version_":1666138491802615810,"score":132.26988}]}